Indivior + Opiant, Regeneron + CytomX, Rezo, Provention
A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals
Find out more at
Indivior + Opiant
Regeneron + CytomX
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.